Sumitomo Pharma Co Ltd 2018 Integrated Report
The report presents Sumitomo Dainippon Pharma's performance for fiscal 2017 (ended March 31, 2018), highlighting the transition to International Financial Reporting Standards (IFRS) and record consolidated revenue of ¥466.8 billion. Key strategic achievements include expanding overseas business, advancing drug pipelines across Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, and completing the SMaRT commercial manufacturing facility. The company actively promotes work style innovation, employee diversity, and sustainability initiatives aligned with the UN Sustainable Development Goals.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2018
Type: Integrated Report
Pages: 138
Back to company
Sumitomo Pharma Co Ltd
Integrated Report
The report presents Sumitomo Dainippon Pharma's performance for fiscal 2017 (ended March 31, 2018), highlighting the transition to International Financial Reporting Standards (IFRS) and record consolidated revenue of ¥466.8 billion. Key strategic achievements include expanding overseas business, advancing drug pipelines across Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, and completing the SMaRT commercial manufacturing facility. The company actively promotes work style innovation, employee diversity, and sustainability initiatives aligned with the UN Sustainable Development Goals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Total Waste
Women on Board
Women in Management
Employees